Moffitt: A Lifelong Passionate Mission Ties Tampa (FL) To Blowing Rock
Blowing Rock News – July 13
It is unlikely that H. Lee Moffitt’s mother (an innkeeper) or father (welding teacher) ever imagined that their son would grow up to be one of the most powerful figures in Florida government. And certainly they had no idea that he would become the catalyst for developing the fastest growing, National Cancer Institute (NCI) comprehensive cancer center in the United States.
Mesothelioma Clinical Trial Combines Immunotherapy Drugs
Asbestos.com – July 13
Dr. Tawee Tanvetyanon at the Moffitt Cancer Center in Tampa rarely sounds this enthused about the future prospects for patients with pleural mesothelioma. Finally, he has something promising to offer.
Tanvetyanon is the principal investigator of a much-anticipated phase II clinical trial involving an immunotherapy drug combination with considerable potential for extending survival.
Amgen’s Blincyto wins full US approval
PharmaTimes – July 13
"Relapsed or refractory ALL is often a lethal disease, with a median overall survival of just four months on standard of care chemotherapy," said Bijal Shah, medical oncologist at the Moffitt Cancer Center in Tampa, Florida. Also seen in Targeted Oncology, Drug Store News, ASCO Post.
New CAR-T cancer treatment offers hope for those with few options
USA Breaking News – July 12
“Your body has many different soldiers within it that that could fight a ground war or a sea war or a land war,” said Dr. Frederick Locke, an oncologist at Moffitt Cancer Center in Tampa, Florida, who’s been testing the approach. Related: Immune Therapy Shows Hope for Ovarian Cancer
Amgen (AMGN) Granted FDA Approval for BLINCYTO (blinatumomab)
Street Insider – July 12
"Relapsed or refractory ALL is often a lethal disease, with a median overall survival of just four months on standard of care chemotherapy," said Bijal D. Shah, M.D., medical oncologist, Moffitt Cancer Center, Tampa, Fla. Also seen on Drugs.com, KOAMTV.com, IT Business Net, ADVFN,
Proscia wants to bridge technology gap in cancer research
MedCity News – July 11
A digital pathology startup founded by technologists from Johns Hopkins, Moffitt Cancer Center in Tampa, the Ohio State University College of Medicine, and the University of Pittsburgh wants to shake up the world of pathology.
T-cell model helps maximize abscopal response
Medical Physics Web – July 10
To help predict the spread of T-cells after radiotherapy, a team at the H Lee Moffitt Cancer Center & Research Institute has built a mathematical framework that simulates systemic T-cell distribution patterns.
Tourism’s a blast in Florida
The Villages Daily Sun – July 9
A Florida Tax Watch report on medical tourism also cited the Moffitt Cancer Center in Tampa and UF Health Shands Hospital in Gainesville as other facilities that have accommodated patients outside the state.
Filling an Unmet Need in MDS Treatment
Cure Magazine – July 7
Rami S. Komrokji, M.D., clinical director of Hematologic Malignancies at Moffitt Cancer Center, discusses an unmet need in the treatment of myelodysplastic syndrome (MDS).
July 11 benefit show to support Jeremy and Lucy Barrett in her cancer battle
FigureSkatersOnline – July 7
Jeremy and Lucy’s son, Watson Harold Barrett, was born in May, premature, but healthy. Lucy is receiving treatment for the disease at Moffitt Cancer Center in Tampa, and the skating community has rallied around her in this fight.
Updated Results From ZUMA-1 Show “Promising” Response Rates With CAR T-Cell Therapy in Relapsed/Refractory NHL
ASH Clinical News – July 7
Treatment with the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel led to a high objective response rate (ORR) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL), according to updated results of the phase I/II ZUMA-1 trial presented at the 2017 ASCO Annual Meeting. Frederick Locke, MD, from the Department of Blood and Marrow Transplant and Cellular Immunotherapy at Moffitt Cancer Center and Research Institute in Tampa, Florida, shared the new data, which expand on interim data initially reported at the 2016 ASH Annual Meeting.
Please note we cannot guarantee the accuracy or availability of links. The stories belong to the respective publishers, and links may expire. Some news sites require you to register and select a password in order to retrieve articles, but most usually do not charge a fee to retrieve these news stories.